Purpose To review the current therapeutic options for the management of diabetic
retinopathy (DR) and diabetic macular edema (DME) and examine the evidence for …

Diabetic macular edema (DME) is the most common cause of vision loss in patients with
diabetic retinopathy with an increasing prevalence tied to the global epidemic in type 2 …

Objective The objective is to formulate clinical practice guidelines for the treatment of
diabetes in older adults. Conclusions Diabetes, particularly type 2, is becoming more …

Background/Aim To assess visual acuity (VA) outcomes and antivascular endothelial growth
factor (anti-VEGF) treatment intensity in diabetic macular oedema (DMO). Methods …

Drug delivery to the suprachoroidal space (SCS®) has become a clinical reality after the
2021 FDA approval of CLS-TA, a triamcinolone acetonide injectable suspension for …

Diabetic macular edema (DME) is a chronic condition with a multifactorial pathogenesis.
Vascular endothelial growth factor (VEGF) and several inflammatory mediators are …

Purpose To determine visual acuity (VA) and spectral-domain optical coherence
tomography (OCT) outcomes with intravitreal ranibizumab for diabetic macular edema …

Introduction Non-exudative (dry) age-related macular degeneration (AMD) and diabetic
macular edema (DME) are leading causes of vision loss worldwide. Besides age-related …

Purpose This study evaluated the potential safety, efficacy, and durability advantages of
investigational triamcinolone acetonide suspension (CLS-TA; Clearside Biomedical …

Diabetic macular edema (DME), characterized by exudative fluid accumulation in the
macula, is the most common form of sight-threatening retinopathy in patients with diabetes …